Risk Stratification in Multiple Myeloma: Putting the Pieces Together
While the past few years have shown an unprecedented increase in the number of agents available to treat patients with multiple myeloma, many advanced practitioners struggle with optimal agent choice, timing, and sequencing, especially related to the use of these newer agents in combination regimens. Learn about these aspects of treatment, as well as testing and diagnosis, risk stratification, emerging toxicities, and supporting patients on oral therapies.
Posted: 1/22/2018 / Expires: 1/22/2019
Estimated time to complete: 1 hour and 30 minutes